Get started
Author

Annette Tavernaro

Observed names: A. Tavernaro, Annette TAVERNARO
Institution: Transgene (France)
OpenAlex ID: A5063810038
Therapeutic vaccination with TG4010 and first-line chemotherapy in advanced non-small-cell lung cancer: a controlled phase 2B trial
2011 · Elisabeth Quoix, Rodryg Ramlau, et al. · The Lancet Oncology · 269
TG4010 immunotherapy and first-line chemotherapy for advanced non-small-cell lung cancer (TIME): results from the phase 2b part of a randomised, double-blind, placebo-controlled, phase 2b/3 trial
2015 · Elisabeth Quoix, Hervé Lena, et al. · The Lancet Oncology · 212
UV light selectively coinduces supply pathways from primary metabolism and flavonoid secondary product formation in parsley
2000 · Elke Logemann, Annette Tavernaro, et al. · Proceedings of the National Academy of Sciences · 178
Phase Ib/II trial of tipapkinogene sovacivec, a therapeutic human papillomavirus16-vaccine, in combination with avelumab in patients with advanced human papillomavirus16-positive cancers
2023 · Edith Borcoman, Ana Lalanne, et al. · European Journal of Cancer · 23
Phase Ib/II trial of TG4001 (Tipapkinogene sovacivec), a therapeutic HPV-vaccine, and Avelumab in patients with recurrent/metastatic (R/M) HPV-16+ cancers
2019 · C. Le Tourneau, J.-P. Delord, et al. · Annals of Oncology · 21
PDF
Biomarkers associated with clinical outcome in advanced non-small cell lung cancer patients treated with TG4010
2009 · B. Acres, E. Quoix, et al. · Journal of Clinical Oncology · 12
Safety and immunogenicity of TG4050: A personalized cancer vaccine in head and neck carcinoma.
2023 · Christian H.H. Ottensmeier, Jean-Pierre Delord, et al. · Journal of Clinical Oncology · 11
Randomized phase I trial of adjuvant personalized cancer vaccine TG4050 in resected locally advanced (LA) head and neck squamous cell carcinoma (HNSCC) patients (pts).
2025 · Christophe Le Tourneau, Jean-Pierre Delord, et al. · Journal of Clinical Oncology · 10
PDF
Phase 1 studies of personalized neoantigen vaccine TG4050 in ovarian carcinoma (OC) and head and neck squamous cell carcinoma (HNSCC).
2022 · Jean-Pierre Delord, Matthew Stephen Block, et al. · Journal of Clinical Oncology · 9
Results of the phase IIb part of TIME study evaluating TG4010 immunotherapy in stage IV non-small cell lung cancer (NSCLC) patients receiving first line chemotherapy.
2015 · Elisabeth A. Quoix, Frederic Forget, et al. · Journal of Clinical Oncology · 8
Randomized phase II trial evaluating the combination of TG4001, an HPV16 therapeutic vaccine, and avelumab (ave) in patients (pts) with immunotherapy-naïve recurrent and/or metastatic (R/M) HPV16-positive cervical or anogenital cancer.
2025 · Christophe Le Tourneau, Frederic Rolland, et al. · Journal of Clinical Oncology · 7
PDF
63MO TG4001 therapeutic vaccination combined with PD-L1 blocker avelumab remodels the tumor microenvironement (TME) and drives antitumor responses in human papillomavirus (HPV)+ malignancies
2020 · C. Le Tourneau, P. Cassier, et al. · Annals of Oncology · 5
PDF
793 TG4001 (Tipapkinogene sovacivec) and avelumab for recurrent/metastatic (R/M) human papilloma virus (HPV)-16+ cancers: clinical efficacy and immunogenicity
2020 · Christophe Le Tourneau, Philippe Cassier, et al. · 4
Time, a Phase 2B/3 Study Evaluating Tg4010 in Combination with First Line Therapy in Advanced Non Small Cell Lung Cancer (Nsclc). Phase 2B Results
2014 · E. Quoix, G. Losonczy, et al. · Annals of Oncology · 4
A viral-based individualized neoantigen vaccine as adjuvant treatment in resected head and neck squamous cell carcinoma: a randomized Phase I trial
2026 · Christian Ottensmeier, Jean-Pierre Delord, et al. · Nature Communications · 1
PDF
650 Randomized phase I trial of adjuvant individualized TG4050 vaccine in patients with locally advanced resected HPV-negative head and neck squamous cell carcinoma (HNSCC)
2024 · Christophe Le Tourneau, Jean-Pierre Delord, et al. · Regular and Young Investigator Award Abstracts · 1
Immunogenicity and clinical activity of tipapkinogen sovacivec (TG4001), an HPV-16 cancer vaccine: A randomized phase 2 study in advanced anogenital cancers.
2023 · Christophe Le Tourneau, Frederic Rolland, et al. · Journal of Clinical Oncology · 1
PDF
Abstract LB205: Feasibility and immunogenicity of adjuvant TG4050, a patient tailored cancer vaccine in head and neck and ovarian cancer
2023 · Ana Lalanne, Camille Jamet, et al. · Cancer Research · 1
Abstract CT182: Phase I trials of personalized cancer vaccine TG4050 in surgically treated high-risk head and neck squamous cell carcinoma (HNSCC) and relapsing ovarian cancer (OvC) patients
2022 · Matthew S. Block, Jean-Pierre Delord, et al. · Cancer Research · 1
Viral-based individualized neoantigen vaccine as adjuvant treatment in resected head and neck squamous cell carcinoma: immunogenicity and efficacy from a randomized Phase I trial
2026 · C. Ottensmeier, J-P. Delord, et al. · medRxiv
PDF
502 Profiling of the neoantigen-specific T cell response after adjuvant TG4050 individualized therapeutic vaccination in a randomized phase I trial for locally advanced resected HPV-negative HNSCC
2025 · Christophe Le Tourneau, Ana Lalanne, et al. · Regular and Young Investigator Award Abstracts
PDF
1592eP Pooled safety analysis of Modified Vaccinia virus Ankara-based therapeutic vaccine alone or in combination in cancer and cervical intraepithelial neoplasia (CIN) clinical trials
2025 · C.H.H. Ottensmeier, C. Le Tourneau, et al. · Annals of Oncology
PDF
Abstract CT045: A randomized phase II trial of TG4001 plus avelumab versus avelumab alone in recurrent/metastatic (R/M) human papilloma virus (HPV)-16 positive anogenital cancers
2023 · Christophe Le Tourneau, Frédéric Rolland, et al. · Cancer Research
Works count: 23
Citation count: 778
H-index: 9
I10-index: 8
Year
Topic
Type